Am I at risk for
prostate cancer?
Do I need to
get a biopsy?
I've been diagnosed.
What should I do?
What Should I
Ask My Doctor?

Understanding Prostate Cancer

1 in 7 Men Will Be Diagnosed

Although prostate cancer is the most common non-skin cancer in America, most men diagnosed will not die from the disease.

What are YOUR risks?

learn more

Am I at risk for
prostate cancer?

1 in 7 Men Will Be Diagnosed

Although prostate cancer is the most common non-skin cancer in America, most men diagnosed will not die from the disease.

What are YOUR risks?

learn more

The Prostate Biopsy

A prostate biopsy is a procedure to remove suspicious prostate gland tissue samples in order to determine if cancer or other abnormal cells are present.

Most prostate biopsies can take place within your urologist’s office.

learn more

Do I need to
get a biopsy?

The Prostate Biopsy

learn more

A Positive Diagnosis

Although you were positively diagnosed with prostate cancer, it’s helpful to understand your specific prostate cancer in order to determine the right path of treatment for you.

Be proactive. Learn more about your specific disease.

learn more

I've been diagnosed.
What should I do?

A Positive Diagnosis

learn more

More Information for Better Decisions

Make sure you know the facts and understand all of your options. Review this list of questions to ask your doctor.

Looking for more information about prostate cancer? There are many reputable organizations which can provide additional information and resources.

learn more

What Should I
Ask My Doctor?

More Information for Better Decisions

learn more

Advanced diagnostic and prognostic solutions for urological cancer care

No matter which test(s) you receive from our growing portfolio of traditional and breakthrough products and services, rest assured they are backed by our superior clinical expertise and the
highest level of customer support.

Press Release

ProMark® Prostate Cancer Prognostic now included in NCCN Guidelines

Metamark, a leader in commercializing high-value urologic oncology products, today announced that ProMark®, the first and only protein-based prognostic test for early-stage prostate cancer, has been included in the 2016 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.

read article

Press Release

Study Demonstrates Cost-effectiveness of New Assay to Inform Treatment Decisions Compared to Guidelines-based Care

Data published in The Oncologist support use of ProMark® as a likely cost-effective addition to current guidelines for management of Gleason 3+3 and 3+4 early-stage prostate cancer.

read article

Displaying results 3-4 (of 12)

|< < 1 - 2 - 3 - 4 - 5 - 6 > >|